Thursday, October 27, 2022 1:54:01 AM
About ANITAC™ Degraders Androgen receptor signaling is the main driver of prostate cancer progression and remains a crucial target for therapeutic intervention in late stages of the disease. While current antiandrogen therapies that directly or indirectly target the AR ligand-binding domain (LBD) are initially effective, resistance ultimately develops and new methods of inhibiting the AR pathway are needed.
ESSA's novel approach of targeting the N-terminal domain of the AR represents a new method of blocking AR signaling. Leveraging ESSA's scientific foundation in successfully targeting the NTD of the AR with a new class of small molecules called anitens, ESSA is developing the first generation of ANITen bAsed Chimera degraders targeting the AR NTD. In preclinical models, the orally bioavailable ANITAC degraders can eliminate forms of AR protein found in castration-resistant prostate cancer that can potentially drive disease progression including LBD mutants and LBD truncated splice variants.
Recent EPIX News
- ESSA Pharma to Present at the Jefferies Global Healthcare Conference • PR Newswire (Canada) • 05/30/2024 12:00:00 PM
- ESSA Pharma to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:01:47 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 11:00:36 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 • PR Newswire (Canada) • 05/14/2024 11:00:00 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 • PR Newswire (US) • 05/14/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 09:17:29 PM
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference • PR Newswire (US) • 04/09/2024 12:00:00 PM
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference • PR Newswire (Canada) • 04/09/2024 12:00:00 PM
- ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS • PR Newswire (US) • 03/08/2024 01:13:00 AM
- ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS • PR Newswire (Canada) • 03/08/2024 01:13:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 10:18:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:50:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 12:01:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 12:01:41 PM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 • PR Newswire (Canada) • 02/13/2024 12:00:00 PM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 • PR Newswire (US) • 02/13/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 04:29:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:27:19 PM
- ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (Canada) • 02/06/2024 01:00:00 PM
- ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 02:15:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2024 09:40:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2024 09:27:10 PM
- ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium • PR Newswire (Canada) • 01/25/2024 03:00:00 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM